Prollenium Adds RENEW™+ Skin Booster to the REVANESSE® Collection
Article content
The product marks a new era for dermal injections with long-lasting hydration to improve skin quality from the inside out.
Article content
Article content
RICHMOND HILL, Ontario — Prollenium, a global leader in medical aesthetic technology, launches Renew™+ to the Revanesse ® family of dermal fillers in Canada. Available immediately, Revanesse® Renew™+ is a unique skin booster that combines low and high molecular weight hyaluronic acid (HA) to hydrate and rejuvenate the skin below the surface, improving skin texture and creating a smoother, more radiant appearance.
Article content
Unlike traditional fillers, Revanesse® Renew™+ is a skin-boosting injection made with 100% high-purity, non-cross-linked HA with a low viscosity and easy spreadability. It is ideal for improving skin quality. Injected into the top layers of skin on the face, neck, or chest, it attracts and retains water molecules, adding an extra moisture boost for a refreshed and renewed look.
Article content
'Renew™+ is a first-of-its-kind dermal filler made in Canada and continues the tradition of breakthrough innovations for the family of Revanesse® products,' said Tim Lee, Chief Scientific Officer of Prollenium. Revanesse® Renew™+ marks the next generation of dermal injections, using the latest technology and advancements to create a lasting solution that leaves patients glowing and rejuvenated.
Article content
The Revanesse® family of dermal fillers features multi-purpose HA-based dermal fillers that provide real results instantly with a quick, minimally invasive beauty treatment. Revanesse® Renew+™ penetrates deeply to hydrate from within, reducing the appearance of fine lines and wrinkles for smoother, plumper skin. Works on the skin's surface to firm, tone, and lock in moisture for a more lifted, youthful look.
Article content
'At Prollenium, we're committed to creating top-of-the-line products to help health care providers give patients the refreshed look they've always wanted,' said Walter Geiger, acting CEO of Prollenium. 'This latest product in the Revanesse® line underscores our dedication to equipping providers with the latest technology and advancements in the medical aesthetics industry.'
Article content
Revanesse® Renew™+ is administered via microinjections into the superficial dermis using fine gauge needles, spaced evenly, 1 cm apart across the desired treatment area. For optimal results, it is recommended to have 2 treatments at 4 weeks apart.
Article content
About Prollenium
Prollenium leads the way in facial aesthetics and rejuvenation technology, turning complex science into reliable, effective products. As the first FDA-approved dermal filler manufacturer in North America, Prollenium redefines standards with cutting-edge innovation, exceptional safety, and a portfolio tailored to patient needs.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Style Blueprint
2 days ago
- Style Blueprint
Meet Deeannah Seymour, Founder of pH-D Feminine Health
Share with your friends! Pinterest LinkedIn Email Flipboard Reddit Deeannah Seymour turned an awkward problem into an entrepreneurial revolution. After discovering boric acid could solve a deeply personal issue, she founded pH-D Feminine Health and launched a quiet uprising in women's wellness. What began with a single product has grown into a movement of education and empowerment. Meet the woman sparking smarter conversations and redefining how we care for our bodies, Deeannah Seymour. Pin What first sparked the idea for pH-D Feminine Health? It's true what they say … necessity is the mother of invention. I had struggled with my own feminine care issues, and I was looking for a holistic solution backed by science. I found it in an ingredient called boric acid, in the form of vaginal suppositories. This ingredient changed my life, and I knew I had to find a way to bring it to market, knowing it would benefit millions of women. Have you found it tricky to start the dialogue about feminine health? Since day one of starting pH-D, we have been intentional about creating a platform where we can have open, honest conversations surrounding feminine health. Our brand was one of the first to openly discuss and educate on two of the top reasons women will visit a doctor: feminine odor and itch. In doing so, we're working to remove the shame and stigma associated with these deeply personal issues that most women experience at some point in their lives. It's been incredible to witness the effects of creating a safe space for these conversations. Women (and men alike) are engaging and tagging each other … all in an effort to lift each other up and help friends or loved ones find solutions for their feminine health issues. We're proud to announce the launch of our boldest initiative yet: Raise Your Vagina iQ™, a nationwide campaign that kicked off with two billboards in Times Square, joined by the always-fabulous Sonja Morgan of The Real Housewives of New York City. This movement was born from a decade of witnessing just how many women struggle to describe what's happening with their own bodies because they were never taught the accurate, anatomical language to do so. Instead, many were encouraged to use vague or 'softer' terms, reinforcing the idea that real words are somehow inappropriate. That language gap has real consequences, especially in medical settings, where too often, women don't receive the care they need simply because they can't clearly express their symptoms. To help bridge that gap, we created a fun, accessible online quiz and educational platform that empowers women (and men!) to better understand and communicate about feminine health. Are you a VagiNewbie, a VaGenius, or maybe even a VaGedictorian? Take the quiz and find out because smarter words lead to smarter care. Pin Women's health has often been misunderstood or ignored. How did you decide where to begin making a difference in such a sensitive space? It's no secret that women's health has historically been underfunded, under-researched, and undervalued — and our story is a powerful example of that. The solution I brought to market, boric acid suppositories, had been used for decades but was only available through expensive, inconvenient compounding pharmacies. Legacy companies overlooked it entirely because there was no intellectual property protection, meaning anyone could replicate the product once it was launched. That didn't stop me. I wasn't motivated by exclusivity; I was driven by purpose. I had experienced firsthand how life-changing this product could be, and I felt a moral obligation to make it accessible to the millions of women who needed it. We didn't expect just how massive the unmet need truly was. By introducing boric acid suppositories into mainstream retail, we didn't just launch a product — we created an entirely new category in the feminine care industry. And that category has given women across the country a safe, effective, affordable alternative they didn't even know was possible. Pin What are some of your most memorable 'pinch-me' moments? Some of my most unforgettable 'pinch-me' moments come from conversations with our customers and the healthcare providers who trust and recommend our products. I've had thousands of deeply moving interactions — many tearful — where women have shared that our products changed their lives, restored their confidence, saved their marriages, or finally gave them relief after years of suffering. Providers have told me we've transformed how they practice medicine and helped them significantly reduce their reliance on antibiotics. There's no greater reward than knowing the work my team and I are doing is truly making a global impact on women's health. Where do you see the conversation around women's wellness heading in the next few years, and what change would you love to see? Over the past two years, we've seen a powerful shift in the conversation around women's health, particularly when it comes to menopause. And it's long overdue. My own mother endured menopause in silence because it simply wasn't talked about. Today, thanks to high-profile women who are openly sharing their experiences, more women feel empowered to speak up, seek care, and finally feel seen. As a result, many are reclaiming their health, energy, and lives. That said, we still have a long way to go, especially when it comes to equitable representation in clinical trials and the development of treatments truly tailored to women. But I believe we're at a tipping point. Women are starting to demand better care for themselves and future generations. And that demand is what will ultimately lead to better outcomes, better innovation, and a dramatically improved quality of life for women everywhere. Pin You spend a lot of time helping others. What do you do to embrace your own self-care? I'm on the road for at least six months of the year. A year ago, with a renewed focus on my health, I joined an all-women's gym called TNB Fitness. When I'm in town, I get up at 5 a.m. so I can be in the gym at 6 a.m. and in the office by 8 a.m. When I'm on the road, I get to the hotel gym or try to move as much as I can. Sometimes, it's a fast-paced walk (or run) through the airport. I also love my pop-up infrared sauna. What's something about you that might surprise people? I am a living organ donor, an experience that forever changed my life. Nearly 11 years ago, I donated a kidney to my friend's four-year-old son, Jake. Saying yes to that decision taught me one of the greatest lessons of my life: how to quiet the noise, listen to where we're being guided, and choose faith over fear. Pin What's the best piece of advice you've ever received? One of the most lasting lessons my dad taught me was simple: 'Whatever is worth doing, is worth doing well.' That quote still sits on my desk today. He reminded us often that no task, no matter how small or routine, was beneath our best effort. Whether it was a major project or a menial chore, doing it well meant doing it with integrity, so it wouldn't have to be redone or regretted. That mindset has stayed with me throughout my life and career. Outside of faith, family, and friends, what three things can't you live without? Bow (our black German Shepherd), Mexican food, and traveling. ********** For more inspiring stories, visit our FACES archives! About the Author Jenna Bratcher Jenna Bratcher is StyleBlueprint Nashville's Associate Editor and Lead Writer. The East Coast native moved to Nashville 17 years ago, by way of Los Angeles. She is a lover of dogs, strong coffee, traveling, and exploring the local restaurant scene bite by bite.
Cision Canada
2 days ago
- Cision Canada
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
Cision Canada
4 days ago
- Cision Canada
Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells Français
If approved, Zemcelpro ® is expected to: increase access to donor-derived stem cell transplantation, which offers a potentially curative option for haematologic malignancies, including leukemias and myelodysplastic syndromes be the first and only therapy in the European Union with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available Approval decision from the European Commission expected within approximately two months MONTREAL, June 19, 2025 /CNW/ - ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and metabolic fitness, announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending granting conditional marketing authorization for Zemcelpro ® for the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available. The European Commission (EC) is expected to make a final decision within approximately two months following CHMP recommendation, and the decision will apply to all 27 European Union (EU) Member States, Iceland, Norway and Liechtenstein. Zemcelpro ®, also known as UM171 Cell Therapy, is a novel cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. If approved, Zemcelpro ® is expected to be the first and only therapy in the EU with marketing authorization for adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available. Every year in Europe there are over 10,000 new cases of patients with haematological malignancies, including leukemias and myelodysplastic syndromes, requiring bone marrow transplant, and a number of these patients do not have access to suitable donor cells for different reasons, including the absence or unavailability of suitably matched donors. The positive CHMP opinion was based on the conditional Marketing Authorization Application (MAA) for Zemcelpro ®. Additional filings are planned for Zemcelpro ® with other health authorities, including in the US, Canada, the UK, and Switzerland. "Each year, thousands of people in Europe are diagnosed with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation, and it's an upsetting reality that a number of them don't have access to suitable donor-derived stem cells," said Dr. Guy Sauvageau, CSO and Founder of ExCellThera. "With today's positive opinion, we are closer to bringing the life-changing potential of Zemcelpro ® to patients with at-risk haematological malignancies in the EU," said David Millette, CEO of ExCellThera. "We are proud to bring our transformative cell therapy innovation to patients who continue to have unmet medical needs." The safety of Zemcelpro ® is consistent with the well-characterized safety profile of conventional allogeneic blood stem cell transplantation for haematological malignancies following myeloablative conditioning. ExCellThera extends its sincere gratitude to the patients and investigators who have contributed to the clinical development of Zemcelpro ®. About Zemcelpro ® Zemcelpro ®, also known as UM171 Cell Therapy, is a novel cryopreserved haematopoietic stem cell transplantation product containing two components, namely UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, each derived from the same cord blood unit. Zemcelpro ®, developed by Cordex Biologics, a wholly owned subsidiary of ExCellThera, has been evaluated in 120 patients with haematologic malignancies in clinical trials in the United States, Europe and Canada. Zemcelpro ® has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designations from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA. Zemcelpro ® has been tested in Phase 2 trials in patients with high and very high-risk acute leukemias and myelodysplasias who have limited treatment options with low survival outcomes and high incidence of relapse under the current standard of care, including patients with patients with TP53 mutations or other genetic abnormalities, patients requiring a second transplant, and patients with refractory or active disease. A pivotal Phase 3 trial in this patient population will be initiated as soon as possible. The use of Zemcelpro ® in other patient populations, including pediatric patients and patients with non-malignant haematological diseases, is also being explored. The product is not yet approved for marketing by the EMA and remains subject to European Commission decision. Its safety and efficacy have not been established by other regulatory agencies, such as the FDA and Health Canada. About ExCellThera and UM171 Technology ExCellThera is a world leader in enhanced blood stem cell therapies. ExCellThera's proprietary Enhance ™ platform for cell expansion and metabolic fitness is designed to deliver a greater dose of functional therapeutic stem cells by expanding haematopoietic stem cells (HSCs) from any source and counteracting the effects of culture or gene editing induced stress. ExCellThera partners with biopharmas to help them develop best-in-class cell and gene therapies by leveraging the technologies that form the Enhance ™ platform, including the proprietary molecule UM171 which has a first-in-class mechanism of action for ex vivo expansion and metabolic fitness of HSCs. For additional information, visit and follow us on LinkedIn.
